

NOVONESIS A/S SER. B

ISIN: DK0060336014 WKN: - Asset Class: **Stock**

Company

2024/06/14 17:20:00

novonesis

Price

407.40

DKK

Difference

-1.33%(-5.50)



Contact Details

NOVONESIS A/S Tel: +
-- Fax: +
Biologiens Vej 2 Web: <http://www.novonesis.com>
2800 Lyngby E-mail: -

Company Profile

Novonesis A/S engages in the era of biosolutions. It innovates and develops transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024, is headquartered in Lyngby, Denmark.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	9,462,000,000		9,241,000,000		7,823,000,000	
Common stock capital		562,000,000		562,000,000		564,000,000
Fixed assets	19,132,000,000		18,772,000,000		17,405,000,000	
Equity capital of a company		14,351,000,000		14,228,000,000		12,206,000,000
Cash and cash equivalents	1,116,000,000		1,041,000,000		963,000,000	
Accrued liabilities		100,000,000		119,000,000		153,000,000
Other assets	-		-		-	
Current liabilities		7,262,000,000		6,963,000,000		5,673,000,000
Prepayments and accrued income		-		-		-
Non-current liabilities		6,981,000,000		6,822,000,000		7,349,000,000
Different income		-		-		-
Other liabilities		152,000,000		1,113,000,000		1,361,000,000
Total assets	28,594,000,000	28,594,000,000	28,013,000,000	28,013,000,000	25,228,000,000	25,228,000,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	6,756	6,781	6,527
Equity ratio	51.49%	52.19%	49.89%
Debt-equity ratio	94.20%	91.62%	100.46%

Others

	2023	2022	2021
Tax Expense Rate	22.15%	19.07%	19.83%

NOVONESIS A/S SER. B

ISIN: DK0060336014 WKN: - Asset Class: **Stock**

Income statement

	2023	2022	2021
Turnover	17,899,000,000	17,553,000,000	14,951,000,000
Net income	3,024,000,000	3,676,000,000	3,146,000,000
EBIT	550,480,500	631,879,200	534,120,300
Operating income before taxes	3,927,000,000	4,563,000,000	3,928,000,000
Cash Flow	4,152,000,000	4,006,000,000	4,062,000,000
Net interest income	-178,000,000	-149,000,000	-55,000,000
Research and development expenses	1,735,000,000	1,655,000,000	1,662,000,000
Income taxes	870,000,000	870,000,000	779,000,000
Result from investments in subsidiaries, associates and other	-18,000,000	-7,000,000	-4,000,000
Revenues per employee	355,278	347,125	307,175

Board of Directors

Cees de Jong	Chairman of Supervisory Board
Morten Otto Sommer	Member of Supervisory Board
Sharon James	Member of Supervisory Board
Anders Knudsen	Member of Supervisory Board
Anne Breum	Member of Supervisory Board
Heine Dalsgaard	Member of Supervisory Board
Jens Øbro	Member of Supervisory Board
Jesper Brandgaard	Member of Supervisory Board
Kasim Kutay	Member of Supervisory Board
Kevin Lane	Member of Supervisory Board
Kim Stratton	Member of Supervisory Board
Lise Kaee	Member of Supervisory Board
Preben Nielsen	Member of Supervisory Board

Members of Management Board

Ester Baiget	Chairman of Managing Board
Amy Byrick	Member of Executive Committee
Anders Lund	Member of Executive Committee
Claus Crone Fuglsang	Member of Executive Committee
Henrik Joerck Nielsen	Member of Executive Committee
Jacob Vishof Paulsen	Member of Executive Committee
Morten Enggaard Rasmussen	Member of Executive Committee
Rainer Lehmann	Member of Executive Committee
Tina Sejersgard Fano	Member of Executive Committee